Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206603 | 1.00 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL564317 | 1.00 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22034968 | 0.84 | POLB (0.43) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22082567 | 0.84 | POLB (0.43) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL10223175 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL13721603 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL12788615 | 0.81 | POLB (0.63) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL22034564 | 0.80 | OPRK1 (0.42) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL27906694 | 0.78 | POLB (0.76) | POLBL3MBTL1EPHX2DPP4DPP8 | |
| SCHEMBL27976413 | 0.78 | POLB (0.76) | POLBL3MBTL1EPHX2DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-2933333-B1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORP (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20160108400-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2639307-A2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | Bonac Corporation (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2628801-A1 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | Bonac Corporation (JP) | 2013-08-21 | — | — | EP | disclosed |
| EP-2431466-A1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | Bonac Corporation (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | SRRT, SSU72, RPRD2 | POLB 505/4885L3MBTL1 118/4885EPHX2 4177/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | POLB 1863/4885L3MBTL1 3548/4885EPHX2 204/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | POLB 1863/4885L3MBTL1 3548/4885EPHX2 204/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | POLB 112/4885L3MBTL1 188/4885EPHX2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.